Pacira Pharma (PCRX) Reports Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pacira Pharma (PCRX) Tops Q2 EPS by 3c, Revenues Beat
August 6, 2020 8:04 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.12, $0.03 better than the analyst estimate of $0.09. Revenue for the quarter came in at $75.51 million versus the consensus estimate of $72.46 million.
Second Quarter 2020 Financial Results
Total revenues were $75.5 million in the second quarter of 2020, a 26% decrease versus the $102.6 million reported for the second... MorePacira Pharma (PCRX) Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients
August 4, 2020 7:35 AM EDTPacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is March 22, 2021.
The sNDA is based on the... More
